LFVN

Image source: The Motley Fool. Thursday, Aug. 27, 2026 at 4:30 p.m. ET President and Chief Executive Officer - Terrence Moorehead Chief Financial Officer - Carl Aure Operator: Good day, ladies and gentlemen. Thank you for standing by. Welcome to today's conference call to discuss LifeVantage's fourth quarter and fiscal year 2026 results. [Operator Instructions] Hosting today's conference will be Reed Anderson with ICR. As a reminder, today's conference is being recorded. I would now like to turn the conference over to Mr. Anderson. Please go ahead, sir. Reed Anderson: Thank you, and good afternoon, everyone, and welcome to LifeVantage Corporation's conference call to discuss results for the fourth quarter and full fiscal year 2026. Joining the call today from LifeVantage are Terrence Moorehead, President and Chief Executive Officer, and Carl Aure, Chief Financial Officer. By now, everyone should have access to the earnings release, which went out this afternoon at approximately 4:05 p.m. Eastern Time. If you have not received the release, it is available on the Investor Relations portion of LifeVantage's site at www.lifevantage.com. This call is being webcast, and a replay will be available on the company's website as well. Before we begin, we'd like to remind everyone that our prepared remarks contain forward-looking statements, and management may make additional forward-looking statements in response to your questions. These statements do not guarantee future performance, and therefore undue reliance should not be placed upon them. These statements are based on current expectations of the company's management, involve inherent risks and uncertainties, including those identified in the Risk Factors section of LifeVantage's most recently filed Forms 10-K and 10-Q. Please note that during today's call, we will discuss non-GAAP financial measures, including results on an adjusted basis. Management believes these financial measures can facilitate a more complete analysis and greater transparency to LifeVantage's ongoing results of operations, particularly when comparing underlying operating results from period to period. We've included a reconciliation of these non-GAAP measures with today's release. This call also contains time-sensitive information that is accurate only as of the date of this live broadcast, August 27, 2026. LifeVantage assumes no obligation to update any forward-looking projections that may be made in today's release or call. Now I will turn the call over to Terrence Moorehead, President and Chief Executive Officer of LifeVantage. Terrence Moorehead: Thank you, Reed, and good afternoon, everyone. Before we begin, I want to take a moment to thank Michael Beindorff for his stewardship of the business and recognize our leadership team for their support during this transition. Michael stepped in to take on the leadership role, and on behalf of the Board of Directors, I want to thank him for his leadership. With that, I'd like to say that it's truly a privilege to join you today as Chief Executive Officer of LifeVantage. Since joining the company, I've been immersed in the business, meeting employees, talking with our sales organization and customers, reviewing processes, evaluating capabilities and assessing our position in the market. It's only been a few weeks, but my conviction about this company is stronger today than when I accepted the role. What attracted me to LifeVantage was the company's differentiated science, solid balance sheet and economics, and significant untapped potential. Specifically, I believe the company's differentiated science is a critical linchpin to our future success. LifeVantage occupies a unique position in the health and wellness industry, focused on delivering a scientifically grounded platform that helps activate the body's natural biological processes. There are a lot of supplement companies on the market, but there aren't a lot of companies like LifeVantage whose products actually help our bodies do what they're naturally built to do instead of just supplementing our diets. That's a meaningful and powerful distinction, and I believe it gives LifeVantage a real competitive advantage that we intend to leverage. As I look at LifeVantage through a more consumer-focused lens, I see an opportunity for us to build a larger, stronger, more relevant brand. We have compelling science, differentiated products, strong margins, and are targeting a passionate group of consumers that are looking for new ways to improve their health every single day. Those are important building blocks that can create substantial value when paired with focused brand building, disciplined execution, and a consumer-centric growth strategy. My initial impression is that the opportunity in front of us is about unlocking the company's potential by reimagining key aspects of the business. We have an opportunity to revitalize our positioning, reframe how consumers think about our brand, strengthen product storylines, and create a greater understanding of the value of our products. Coming out of the blocks, our early focus will be centered around three priorities. First, strengthening the LifeVantage brand. We have valuable science and differentiated products, but I believe we can do a much better job of communicating our story in a more clear, compelling, and consumer-friendly way. Consumers gravitate towards brands they trust and understand. Building that connection consistently and at scale will be a major focus. Our second priority focuses on building a more relevant consumer proposition. Here, our goal is to arm our sales force with more powerful tools, dramatically improve the consumer experience, and create a larger base of loyal consumers who incorporate LifeVantage in their lives on a daily basis. Our third and final priority will focus on improving operational excellence and profitability. One of the things that immediately stood out to me about LifeVantage were the economics of the business, particularly the gross margins that have historically approached 80% and could create strong opportunities. The challenge will be to effectively translate those economics into sustainable growth and improved shareholder value. Now, I want to be thoughtful about expectations. It's still early in my tenure, so we're not going to be providing any formal guidance at this time. Over the next several months, we'll continue to assess the business and work closely with our leadership team to develop a comprehensive growth strategy supported by clear priorities, measurable objectives, and accountability throughout the organization. What I can tell you today is that I accepted this role because I believe this company has far greater potential than its current scale reflects. I believe in the potential of our brand. I believe in the quality of our products. And I believe in the people behind this business. We have meaningful work ahead of us, but I'm confident that we have what it takes to create long-term value for our sales force, our employees, and our shareholders. I look forward to sharing more about our plans as the work progresses. And with that, I'd like to turn the call over to our Chief Financial Officer, Carl Aure, so he can walk you through our financial results in more detail. Carl? Carl Aure: Thank you, Terrence, and good afternoon, everyone. Let me walk you through our fourth quarter financial results. Please note that I will be discussing our non-GAAP adjusted results where applicable. You can refer to the GAAP to non-GAAP reconciliations in today's press release for additional details. For the fourth quarter of fiscal 2026, we delivered net revenue of $42.4 million, which was down 23.1% compared to $55.1 million in the fourth quarter of fiscal 2025. The decrease was primarily driven by downward pressure in the number of orders from our active account base and lower average order size, reflecting impacts from the broader macroeconomic environment, as well as lower sales of our MindBody GLP-1 System cycling the higher comparable fourth quarter of fiscal 2025, and partially offset by sales of LoveBiome, which we acquired in October 2025. Fourth quarter revenue was down 3.1% sequentially from the third quarter of fiscal 2026. Revenue in the Americas region decreased 24.8% to $32.7 million, and revenue in the Asia-Pacific and Europe region decreased 16.9% to $9.7 million. Subscription-based revenue remains strong, representing more than 75% of our total revenue in the fourth quarter of fiscal 2026, and our customer retention metrics improved year over year. We will continue to look for opportunities to improve our retention metrics for our most loyal customers. As Terrence mentioned earlier, we will also look to strengthen the LifeVantage brand and refine our consumer proposition to expand appeal to new consumers. This will be an area of focus for us as we move forward into fiscal 2027. Our gross profit percentage for the fourth quarter was 78% compared to 79.9% in the prior year period, reflecting a shift in product mix, higher inventory obsolescence expenses, and increases in shipping and related warehouse expenses. Commissions and incentive expense was 41.3% of revenue compared to 42.1% a year ago, reflecting the timing and magnitude of our promotional incentive programs and changes to the sales mix between customers and independent consultants. Selling, general and administrative expenses were 32.7% of revenue compared to 33.9% in the prior year period. Adjusted non-GAAP SG&A was 32.3% of revenue compared to 33.3% in the prior year period, reflecting decreases in variable employee compensation expenses and lower event-related expense. GAAP operating income was $1.7 million compared to $2.1 million in the prior year period. Adjusted non-GAAP operating income was $1.8 million compared to $2.5 million a year ago. GAAP net income was $1.3 million or $0.10 per diluted share compared to $2.0 million or $0.15 per diluted share in the fourth quarter of fiscal 2025. Adjusted non-GAAP net income was $1.4 million or $0.11 per diluted share compared to $2.3 million and $0.17 in the prior year period. We recorded income tax expense of just over $400,000 in the fourth quarter of fiscal 2026. Our overall effective tax rate for fiscal 2026 was approximately 16.4%. Adjusted EBITDA in the fourth quarter was $2.7 million, or 6.5% of revenue, compared to $4.8 million, or 8.7% of revenue in the same period a year ago. Our financial position remains strong, with $14.9 million of cash and no debt at the end of fiscal 2026, compared to $20.2 million of cash a year ago. We generated $10.2 million of cash from operations during fiscal 2026 compared to $11.9 million in the prior year period. We also maintain access to a $5 million revolving line of credit. Capital expenditures totaled $3.6 million in fiscal 2026 compared to $1.4 million in 2025, reflecting our continued investment in technology infrastructure, including the Shopify integration. We also utilized $3.7 million in cash during fiscal 2026 for the LoveBiome transaction. Turning to capital allocation, we repurchased 85,700 shares in the fourth quarter for an aggregate purchase price of approximately $459,000. During fiscal 2026, we repurchased approximately 336,000 shares for an aggregate purchase price of $2.0 million. As of June 30, there was $58.5 million remaining under the new $60 million share repurchase authorization approved by our Board of Directors in January. We also recently announced a quarterly cash dividend of $0.05 per share of common stock that will be paid on September 15, 2026, to shareholders of record as of September 1, 2026. We remain committed to our balanced capital allocation strategy in order to maximize shareholder value. Given the recent transition in our Chief Executive Officer role, we are not issuing formal guidance for fiscal 2027 on today's call. And with that, let me turn the call back over to Terrence. Terrence Moorehead: Before we open the call for questions, I'd like to leave you with some final thoughts. First, despite the challenges reflected in our recent results, I'm very optimistic about the future of LifeVantage. The more I learn about the company, the more convinced I am that we have a unique opportunity and significant white space ahead. Second, because we have a strong financial foundation driven by our debt-free balance sheet, a healthy cash position, and a disciplined approach to capital allocation, we have the flexibility to invest in growth while continuing to return capital to shareholders. Third and finally, we're going to move forward with a sense of urgency. Over the coming months, we'll be working as a team to develop a clear strategic roadmap, establish measurable goals, and align our organization around execution. In closing, I'm very excited about the future and the potential that lies ahead. Now, our focus is on building the brand, accelerating consumer relevance, and executing with discipline so we can fully realize that potential. With that, let's open the line for questions. Operator: [Operator Instructions] Our first question is from Ryan Meyers with Lake Street Capital. Ryan Meyers: Terrence, congrats on the new role. We're just thinking about the revenue side of the business. You know, we saw another sequential decline here in the fourth quarter. Can you maybe just talk about the monthly trends throughout the quarter and maybe what you've seen so far in July and August and understand that you're not giving guidance? But have we seen sort of a stabilization? Have trends improved a little bit? Just any commentary there would be helpful. Terrence Moorehead: I'm going to let Carl handle that one. Carl Aure: Yes, happy to take that, Ryan. Yes, as you mentioned, sequentially we were down just about $1.5 million or so from Q3 into Q4. You know, some of that we've mentioned, we've talked about some of the challenges we face just with declining orders, number of orders that are out there, as well as just we're seeing a little bit of a decline in just the average order size between Q3 and Q4. As we look forward, we're not giving guidance obviously for fiscal 2027, but as you know, looking back at the comparables, we still have a couple of difficult comparables in Q1 and Q2 of our fiscal year next year, and so those will certainly be challenging, but I think as we start to work through the strategies that Terrence and the team are working on here. When we get to our fiscal Q3 into Q4, that's really where we anticipate that we hopefully can turn the trend line and really start to see a little bit of momentum associated with those strategies that we're working on and look to be putting in place at the first part of the year. Ryan Meyers: Okay, got it. And then thinking about the fewer orders and the lower average order size that you had mentioned, did these come specifically from MindBody? Did they come from the broader portfolio, just as we sort of attribute some of these softer KPIs? Was it portfolio? Carl Aure: I can tell you as a whole, there's certain areas that are down. Yes, no, I can talk to some of that. I mean, MindBody definitely has an impact since MindBody was a higher-priced product. So there is certainly some impact from a shift away from MindBody on the average order size. But we also are seeing just some decline in the overall average order size in some of the other categories, not significantly so. You know, and I think also what we're seeing is we're still, you know, our base of loyal customers. We're seeing that base continue to purchase, but, you know, possibly we're seeing, you know, possibly they're pausing a subscription for a month and then picking it up the next month. And so some of that or all of those things are impacting those metrics at the end of the day. Terrence Moorehead: I think there's a fair amount of price pressure that our consumers are under right now, just given what's happening in the economy. And so a couple of our strategies going forward will be looking at how we can strengthen our value proposition, not necessarily by dropping prices, but adding credence to the voice that we have when we're talking about our products in order to attract new customers into the business. Ryan Meyers: Okay. Got it. Well, thank you for taking my question. Operator: Thank you. Our next question is from Linda Weiser with Water Tower Research. Linda Weiser: So, LifeVantage, in terms of the percentage of revenue that's outside of the Americas, it's really small, you know, relative to other direct selling companies. It seems to me that there could be an opportunity to expand the business a lot more outside the Americas. Is that kind of one of your first impressions? And if so, like, how would you prioritize that versus just kind of the things you want to do to the core business as it is now? Thanks. Terrence Moorehead: Yes, I think you're right, Linda. I think clearly international is an opportunity. One of the things that attracted me to LifeVantage is that we're under-penetrated in all of our markets, not just internationally. So I think we have tremendous growth potential here in North America, but also internationally. So we will be moving forward to drive penetration in our kind of existing international markets. I don't know if we're going to expand our footprint further, you know, kind of immediately. I think we're best suited to drive penetration in a couple of anchor markets and then kind of branch out from there, almost in a kind of a hub-and-spoke type of approach. But again, just given the scale of our business in North America, we want to take advantage of that. We want to leverage that, focus on building out that team because we're still, like, we still have a lot of opportunity. And that would be kind of across categories and across, you know, kind of regions within the U.S. Linda Weiser: Okay. And then, I know when you were at your previous company, you really leaned into driving e-commerce sales and you really developed that business in the U.S. in particular. Is that something that you see as an opportunity here too? And what are your thoughts along those lines, thanks. Terrence Moorehead: I think that the opportunities at LifeVantage really focus on, certainly focus on, upgrading capabilities, building out digital capabilities, specifically building out our digital network. We'll see kind of where we take that, but first and foremost, I think we're going to kind of upgrade and update the consumer kind of access points. And so we have a fairly major kind of program to upgrade our website, upgrade our consumer experience. But then we're also going to kind of pair with that, upgrading the tools that we give to our sales force so that they can more effectively go to market in a much more effective and powerful manner with some digital tools in their hands and digital assets in their hands as well. So I definitely believe that digital is going to be a key strategy for us. We'll see how that unfolds. I think a big piece of the strategy also has to focus on being a much more consumer-centric company, being much more relevant to consumers so that we can be more effective on all fronts to improve and increase demand. That's how I'm looking at it right now. Again, I'm still early days, so we need to see what our capabilities are and how we can move forward and how we can make sure that we have this kind of a very much integrated approach to our go-to-market strategy. So I hope that answers your question. Linda Weiser: Yes, thank you. That's very helpful. And then my last question just has to do with, you know, the conversation so far has mentioned upgrades of IT, etc. So I'm just curious about any kind of very rough outlook about capital spending. It's a small percentage of revenue for the company, but it looks like it picked up a little bit in FY '26. Is FY '27 going to be a year of increased spending in dollar terms, or just what do you think is going to be kind of the needed capital in that area? Thanks. Terrence Moorehead: Carl, you want to take that one? Carl Aure: Yes, certainly. Yes, I can take that, Linda. And yes, you're right. Over the year-over-year increase over in the CapEx area, that was really all Shopify-related and upgrading our e-commerce platform. We've made a lot of progress on that Shopify project to date. We're not done yet. We still have, you know, a little ways to go, but I would anticipate the total CapEx spend for FY '27 to be slightly less than that number. And I think in total, we were around $3.7 million or so in fiscal 2026. I would anticipate it's more in the $3 million to $3.5 million range as we close out the final stages of Shopify. And once we're through that, then we're back down to normal CapEx spend, you know, back to the historical levels of the $2 million to $2.5 million. Operator: This concludes our question and answer session. I'll now turn it back to Mr. Moorehead for any closing remarks. Terrence Moorehead: Okay, well, thank you, everybody, for joining us today and for your continuous support. I look forward to talking to you again next quarter, till then take care. Operator: This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation. Before you buy stock in LifeVantage, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and LifeVantage wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $440,710!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,335,252!* Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of August 31, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. LifeVantage (LFVN) Q4 2026 Earnings Call Transcript was originally published by The Motley Fool

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Performance was impacted by downward pressure on active account order volume and lower average order sizes, reflecting a challenging macroeconomic environment for consumers. Management attributes the revenue decline partly to cycling high comparables from the MindBody GLP-1 System launch in the prior year, though this was partially offset by the LoveBiome acquisition. The new CEO identifies the company's 'differentiated science' and biological activation platform as a critical competitive advantage over traditional supplement companies. Strategic priorities are shifting toward strengthening the brand narrative to be more consumer-friendly and improving the digital experience for both customers and the sales force. Gross margins remained high at 78%, providing a strong economic foundation that management intends to translate into sustainable growth through disciplined execution. Customer retention metrics showed year-over-year improvement, with subscription-based revenue remaining a core strength at over 75% of total revenue. The company is addressing price sensitivity by focusing on strengthening its value proposition and 'adding credence' to product storytelling rather than direct price discounting. Formal guidance for fiscal 2027 is withheld as the new CEO conducts a comprehensive business assessment to develop a long-term growth strategy. Management anticipates continued year-over-year pressure in the first half of fiscal 2027 due to difficult comparables, with a projected trend reversal in the third and fourth quarters. Future growth will prioritize driving deeper penetration in existing 'anchor markets' through a hub-and-spoke approach before considering further international footprint expansion. Capital allocation will remain balanced, utilizing a $60 million share repurchase authorization and a quarterly dividend while maintaining a debt-free balance sheet. Strategic investments will focus on upgrading digital access points, including the completion of the Shopify e-commerce integration to enhance the consumer experience. The transition to new CEO Terrence Moorehead marks a shift toward a more consumer-centric and digitally-integrated go-to-market strategy. Capital expenditures increased to $3.6 million in fiscal 2026, primarily driven by the multi-year Shopify platform integration project. Gross profit margins were slightly compressed by 190 basis points due to product mix shifts, higher inventory obsolescence, and increased shipping and warehouse costs. The company maintains a strong liquidity position with $14.9 million in cash and an untapped $5 million revolving line of credit. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management noted that while Q4 saw a sequential decline of approximately $1.5 million, they expect the trend line to turn in the second half of fiscal 2027. The decline was attributed to a shift away from the higher-priced MindBody products and consumers occasionally pausing subscriptions due to economic pressure. The CEO views both domestic and international markets as significantly under-penetrated, representing 'tremendous growth potential'. The immediate focus will be on driving penetration in existing markets rather than opening new territories, leveraging the scale of the North American team. Management plans to upgrade consumer access points and provide the sales force with enhanced digital tools to improve market effectiveness. The strategy emphasizes becoming a 'consumer-centric' company to increase overall demand through an integrated digital approach. CapEx is expected to be slightly lower in fiscal 2027, estimated between $3 million and $3.5 million as the Shopify project nears completion. Once the e-commerce platform upgrade is finalized, management expects CapEx to return to historical levels of $2 million to $2.5 million.

This article first appeared on GuruFocus. Net Revenue: $42.4 million in Q4 fiscal 2026, down 23.1% year-over-year from $55.1 million. Sequential Revenue: Down 3.1% from Q3 fiscal 2026. Americas Revenue: Decreased 24.8% to $32.7 million. Asia-Pacific and Europe Revenue: Decreased 16.9% to $9.7 million. Subscription-Based Revenue: Represented more than 75% of total revenue in Q4 fiscal 2026. Gross Profit Percentage: 78% in Q4 fiscal 2026, down from 79.9% in the prior year period. Commissions and Incentive Expense: 41.3% of revenue, down from 42.1% a year ago. Selling, General and Administrative Expenses: 32.7% of revenue, down from 33.9% in the prior year period. Adjusted Non-GAAP SG&A: 32.3% of revenue, down from 33.3% in the prior year period. GAAP Operating Income: $1.7 million, down from $2.1 million in the prior year period. Adjusted Non-GAAP Operating Income: $1.8 million, down from $2.5 million a year ago. GAAP Net Income: $1.3 million, or $0.10 per diluted share, down from $2.0 million, or $0.15 per diluted share, in Q4 fiscal 2025. Adjusted Non-GAAP Net Income: $1.4 million, or $0.11 per diluted share, down from $2.3 million, or $0.17 per diluted share, in the prior year period. Adjusted EBITDA: $2.7 million, or 6.5% of revenue, down from $4.8 million, or 8.7% of revenue, in the same period a year ago. Cash Position: $14.9 million in cash with no debt at the end of fiscal 2026, compared to $20.2 million a year ago. Cash from Operations: $10.2 million generated during fiscal 2026, down from $11.9 million in the prior year period. Capital Expenditures: $3.6 million in fiscal 2026, up from $1.4 million in 2025. Share Repurchases: 85,700 shares repurchased in Q4 for approximately $459,000; approximately 336,000 shares repurchased during fiscal 2026 for $2.0 million. Dividend: Quarterly cash dividend of $0.05 per share announced, payable on September 15, 2026. Warning! GuruFocus has detected 2 Warning Sign with LFVN. Is LFVN fairly valued? Test your thesis with our free DCF calculator. Release Date: August 27, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. LifeVantage Corp (NASDAQ:LFVN) has a strong financial foundation with $14.9 million in cash, no debt, and access to a $5 million revolving line of credit. The company maintains high gross margins, historically approaching 80%, which provides a solid base for future profitability. Subscription-based revenue remains robust, accounting for over 75% of total revenue, and customer retention metrics improved year over year. LifeVantage Corp (NASDAQ:LFVN) continues to return capital to shareholders through share repurchases and a quarterly cash dividend, with $58.5 million remaining under its buyback authorization. The new CEO, Terrence Moorehead, brings a fresh perspective and has identified clear strategic priorities, including strengthening the brand, enhancing consumer relevance, and improving operational excellence, which could unlock significant untapped potential. LifeVantage Corp (NASDAQ:LFVN) experienced a significant revenue decline of 23.1% year over year in Q4 fiscal 2026, driven by lower order volumes and average order size. The company faces ongoing challenges from a tough macroeconomic environment, which is pressuring consumer spending and impacting sales. Sales of the MindBody GLP-1 System have declined, cycling against a high comparable period and negatively affecting overall revenue and average order size. Gross profit percentage decreased to 78% from 79.9% due to product mix shifts, higher inventory obsolescence, and increased shipping costs. The company is not providing formal guidance for fiscal 2027 due to the CEO transition, creating uncertainty about near-term performance and the timeline for a turnaround. Q: Can you discuss the monthly revenue trends throughout the fourth quarter and what you've seen in July and August? Have trends stabilized or improved?A: Carl Aure (CFO) noted that revenue declined sequentially by about $1.5 million from Q3 to Q4, driven by a decrease in the number of orders and a slight decline in average order size. While not providing formal guidance, he acknowledged that fiscal Q1 and Q2 of 2027 will face difficult year-over-year comparisons. However, the company anticipates that as new strategies are implemented, the trend line could potentially turn positive by fiscal Q3 and Q4. Q: Were the declines in orders and average order size specifically from the MindBody GLP-1 System or from the broader portfolio?A: Carl Aure (CFO) explained that the MindBody product, being higher-priced, had a significant impact on the average order size. However, there were also declines in other categories. He noted that the loyal customer base continues to purchase, but some may be pausing subscriptions for a month before resuming, which affects the overall metrics. Terrence Moorehead (CEO) added that consumers are under price pressure due to the economy, and the company's strategy will focus on strengthening its value proposition by adding credibility to its product messaging rather than dropping prices. Q: Given the small percentage of revenue from outside the Americas, do you see an opportunity to expand internationally? How would you prioritize this versus the core business?A: Terrence Moorehead (CEO) agreed that international expansion is an opportunity, noting that the company is under-penetrated in all its markets, including North America. He stated that the immediate focus will be on driving penetration in existing international markets rather than expanding the footprint. The strategy will involve a "hub and spoke" approach, focusing on a couple of anchor markets before branching out, while also leveraging the scale of the North American business. Q: Given your background in driving e-commerce sales, do you see a similar opportunity at LifeVantage?A: Terrence Moorehead (CEO) confirmed that upgrading digital capabilities is a key focus. The company plans to upgrade its website and consumer experience, as well as provide its sales force with better digital tools and assets to go to market more effectively. He emphasized that becoming a more consumer-centric company and improving demand generation are central to the strategy, though he noted it is still early days in assessing capabilities. Q: What is the outlook for capital spending in fiscal 2027, given the increase in FY26 related to IT upgrades?A: Carl Aure (CFO) stated that the increase in CapEx in fiscal 2026 was primarily related to the Shopify e-commerce platform integration. He anticipates total CapEx for fiscal 2027 to be slightly lower, in the range of $3 million to $3.5 million, as the final stages of the Shopify project are completed. After that, CapEx is expected to return to historical levels of $2 million to $2.5 million. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its fourth fiscal quarter ended June 30, 2026. Fourth Quarter Fiscal 2026 Summary*: Revenue was $42.4 million, a decrease of 23.1% from the prior year period; Revenue in the Americas decreased 24.8%, and revenue in Asia/Pacific & Europe decreased 16.9%; Net income per diluted share was $0.10, versus $0.15 per diluted share a year ago; Adjusted earnings per diluted share was $0.11, compared to $0.17 a year ago; and Adjusted EBITDA was $2.7 million compared to $4.8 million a year ago. * All comparisons are on a year over year basis and compare the fourth quarter of fiscal 2026 to the fourth quarter of fiscal 2025, unless otherwise noted. Fiscal Year 2026 Summary*: Revenue was $182.6 million, a decrease of 20.1% from the prior year period; Revenue in the Americas decreased 23.2%, and revenue in Asia/Pacific & Europe decreased 6.9%; Net income per diluted share was $0.40, versus $0.75 per diluted share a year ago; Adjusted earnings per diluted share was $0.56, compared to $0.82 a year ago; and Adjusted EBITDA was $13.7 million compared to $22.1 million a year ago. * All comparisons are fiscal year 2026 to fiscal year 2025. "It's a privilege to lead LifeVantage at this stage of its journey and my conviction about this Company is stronger today than when I accepted the role," said Terrence Moorehead, President and Chief Executive Officer. "With a differentiated, science-backed platform, strong gross margins and a debt-free balance sheet, our foundation is strong and I believe we have a real competitive advantage. Our early focus will be on strengthening the LifeVantage brand, building a more relevant consumer proposition, and driving operational excellence. Despite the challenges reflected in our recent results, I'm optimistic about what lies ahead. We intend to move forward with a real sense of urgency and look forward to sharing more about our strategy as our work progresses." Fourth Quarter Fiscal 2026 Results For the fourth quarter ended June 30, 2026, the Company reported revenue of $42.4 million, a 23.1% decrease compared to revenue of $55.1 million in the fourth quarter of fiscal 2025. Revenue in the Americas region decreased 24.8% and revenue in the Asia/Pacific & Europe region decreased 16.9%. These decreases were primarily due to due to downward pressure in the number of orders from our active account base and lower average order size, reflecting impacts from the broader macro-economic environment, as well lower sales of our MindBody GLP-1 System cycling the higher comparable fourth quarter of fiscal 2025, partially offset by sales of LoveBiome, which we acquired in October 2025. Gross profit for the fourth quarter of fiscal 2026 was $33.0 million, or 78.0% of revenue, compared to $44.0 million, or 79.9% of revenue, for the same period in fiscal 2025. The decrease in gross profit as a percentage of revenue was primarily due to a shift in product mix, inventory obsolescence expenses, and increases in shipping related expenses. Commissions and incentives expense for the fourth quarter of fiscal 2026 was $17.5 million, or 41.3% of revenue, compared to $23.2 million, or 42.1% of revenue, for the same period in fiscal 2025. The decrease in commissions and incentives expenses as a percentage of revenue compared to the prior year period is primarily due to the timing and magnitude of promotional and incentive programs and changes to the sales mix between customers and independent consultants. Selling, general and administrative (SG&A) expense for the fourth quarter of fiscal 2026 was $13.9 million, or 32.7% of revenue, compared to $18.7 million, or 33.9% of revenue, for the same period in fiscal 2025. The decrease in SG&A expenses as a percentage of revenue was primarily due to decreases in variable employee compensation expenses and lower event related expenses. Operating income for the fourth quarter of fiscal 2026 was $1.7 million compared to $2.1 million for the same period in fiscal 2025. Adjusted non-GAAP operating income for the fourth quarter of fiscal 2026 was $1.8 million compared to adjusted non-GAAP operating income of $2.5 million for the same period in fiscal 2025. Net income for the fourth quarter of fiscal 2026 was $1.3 million, or $0.10 per diluted share, compared to $2.0 million, or $0.15 per diluted share for the same period in fiscal 2025. Adjusted non-GAAP net income for the fourth quarter of fiscal 2026 was $1.4 million, or $0.11 per diluted share, compared to adjusted non-GAAP income of $2.3 million, or $0.17 per diluted share, in the same period of fiscal 2025. Adjusted EBITDA was $2.7 million for the fourth quarter of fiscal 2026, versus $4.8 million for the comparable period in fiscal 2025. Full Year Fiscal 2026 Results For the fiscal year ended June 30, 2026, the Company reported revenue of $182.6 million, a 20.1% decrease compared to revenue of $228.5 million in fiscal 2025. Revenue in the Americas region decreased 23.2% and revenue in the Asia/Pacific & Europe region decreased 6.9%. These decreases were primarily due to declines in sales of the MindBody GLP-1 System®, declines in the number of orders from our active account base, and average order size. These declines were partially offset by sales of LoveBiome, which the Company acquired in October 2025. Gross profit for fiscal 2026 was $141.6 million, or 77.6% of revenue, compared to $183.7 million, or 80.4% of revenue in fiscal 2025. The decrease in gross profit as a percentage of revenue was primarily due to an allowance for inventory obsolescence related to the MindBody GLP-1 System®, along with a shift in product mix. Adjusted for the allowance for inventory obsolescence, non-GAAP gross profit for fiscal 2026 was $144.1 million, or 78.9% of revenue. Commissions and incentives expense for fiscal 2026 was $77.1 million, or 42.2% of revenue, compared to $102.3 million, or 44.7% of revenue in fiscal 2025. The decrease in commissions and incentives expenses as a percentage of revenue compared to the prior year is primarily due to changes in the sales mix between our independent consultants and customers along with the timing and magnitude of promotional and incentive programs. Selling, general and administrative (SG&A) expense for fiscal 2026 was $58.4 million, or 32.0% of revenue, compared to $69.2 million, or 30.3% of revenue in fiscal 2025. The increase in SG&A expenses as a percentage of revenue was primarily due to an overall decrease in sales during the year partially offset by decreases in the variable portion of employee related compensation expenses. Operating income for fiscal 2026 was $6.1 million compared to $12.2 million in fiscal 2025. Adjusted non-GAAP operating income for fiscal 2026 was $8.6 million compared to adjusted non-GAAP operating income of $13.3 million in fiscal 2025. Net income for fiscal 2026 was $5.1 million, or $0.40 per diluted share, compared to $9.8 million, or $0.75 per diluted share in fiscal 2025. Adjusted non-GAAP net income for fiscal 2026 was $7.2 million, or $0.56 per diluted share, compared to adjusted non-GAAP income of $10.6 million, or $0.82 per diluted share in fiscal 2025. Adjusted EBITDA was $13.7 million in fiscal 2026 versus $22.1 million in fiscal 2025. Balance Sheet & Liquidity The Company generated $10.2 million of cash from operations during fiscal 2026 compared to $11.9 million in fiscal 2025. The Company's cash and cash equivalents at June 30, 2026 were $14.9 million, compared to $20.2 million at June 30, 2025, and there was no debt outstanding. Share Repurchase During fiscal 2026, the Company repurchased approximately 336,000 of its common shares for an aggregate price of approximately $2.0 million. As of June 30th, there was $58.5 million remaining under the $60 million share repurchase program approved by the Company’s Board of Directors in January. Fiscal 2027 Guidance Due to the recent transition in the Chief Executive Officer role, the Company is not issuing formal guidance for fiscal 2027 at this time. Conference Call Information The Company will hold an investor conference call today at 2:30 p.m. MST (4:30 p.m. EST). Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, September 17, 2026, by dialing (844) 512-2921 from the U.S. and entering confirmation code 13761673, or (412) 317-6671 from international locations, and entering confirmation code 13761673. There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at https://investor.lifevantage.com/events-and-presentations. The webcast will be archived for approximately 30 days. About LifeVantage Corporation LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the MindBody GLP-1 System®, the newest comprehensive gut activator from LoveBiome P84, the Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic and hydration energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com. Cautionary Note Regarding Forward Looking Statements This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," “may be,” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The declaration and/or payment of a dividend during any quarter provides no assurance as to future dividends, and the timing and amount of future dividends, if any, could vary significantly in comparison both to past dividends and to current expectations. Examples of forward-looking statements include, but are not limited to, expected financial performance, including revenue margins, statements we make regarding executing against and the benefits of our key initiatives, future growth, including geographic and product expansion, and expected dividend payments in future quarters. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, further deterioration to the global economic and operating environments, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission (the “SEC”). The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law. About Non-GAAP Financial Measures We define Non-GAAP EBITDA as earnings before interest expense, income taxes, depreciation and amortization and Non-GAAP Adjusted EBITDA as earnings before interest expense, income taxes, depreciation and amortization, stock compensation expense, other income, net, and certain other adjustments. Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We define Non-GAAP Net Income as GAAP net income less certain tax adjusted non-recurring one-time expenses incurred during the period and Non-GAAP Earnings per Share as Non-GAAP Net Income divided by weighted-average shares outstanding. We are presenting Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share because management believes that they provide additional ways to view our operations when considered with both our GAAP results and the reconciliation to net income, which we believe provides a more complete understanding of our business than could be obtained absent this disclosure. Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share are presented solely as supplemental disclosure because: (i) we believe these measures are a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing shareholder value; and (iii) we use Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share internally as benchmarks to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share has limitations and you should not consider these measures in isolation from or as an alternative to the relevant GAAP measure of net income prepared in accordance with GAAP, or as a measure of profitability or liquidity. The tables set forth below present reconciliations of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share, which are non-GAAP financial measures to Net Income and Earnings per Share, our most directly comparable financial measures presented in accordance with GAAP. Investor Relations Contacts: Reed Anderson, ICR (646) [email protected]

Interested in Lifevantage Corporation? Here are five stocks we like better. Revenue and profitability declined: Fourth-quarter revenue fell 23.1% year over year to $42.4 million, pressured by fewer orders, smaller order sizes and weaker MindBody GLP-1 System sales. Adjusted EBITDA dropped to $2.7 million from $4.8 million. New CEO is prioritizing a turnaround: Terrence Moorehead plans to strengthen the brand, clarify the consumer product proposition, improve sales-force tools and boost operational efficiency. LifeVantage did not provide fiscal 2027 guidance because of the leadership transition. Financial position remains stable: The company ended fiscal 2026 with $14.9 million in cash, no debt and access to a $5 million credit line, while continuing share repurchases and paying a quarterly dividend of $0.05 per share. GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends Lifevantage (NASDAQ:LFVN) reported lower fourth-quarter and fiscal 2026 results as the health and wellness company faced fewer orders, lower average order sizes and a difficult comparison against prior-year sales of its MindBody GLP-1 System. For the fourth quarter ended June 30, net revenue declined 23.1% to $42.4 million from $55.1 million in the prior-year period. Revenue fell 3.1% sequentially from the fiscal third quarter. The Americas region posted a 24.8% decline in revenue to $32.7 million, while Asia-Pacific and Europe revenue decreased 16.9% to $9.7 million. → Quantum Computing Is Raising the Stakes for Cybersecurity: 5 Stocks to Watch Chief Financial Officer Carl Aure said the revenue decline primarily reflected pressure on order volumes from the active account base and lower average order size. The results also reflected lower MindBody GLP-1 System sales against a stronger prior-year comparison, partly offset by contributions from LoveBiome, which LifeVantage acquired in October 2025. More than 75% of fourth-quarter revenue came from subscriptions, Aure said, while customer retention metrics improved from a year earlier. He added that some loyal customers continued purchasing but may have paused a subscription for a month before resuming it, affecting reported metrics. → NVIDIA Reveals $21 Billion SpaceX Stake: Signal of Confidence or Circular Financing? Fourth-quarter gross profit margin was 78.0%, compared with 79.9% a year earlier. Aure attributed the decrease to product mix, higher inventory obsolescence expense, and increased shipping and warehouse-related costs. Commissions and incentive expense represented 41.3% of revenue, down from 42.1% in the prior-year quarter, due to the timing and magnitude of promotional incentive programs and changes in the sales mix between customers and independent consultants. Selling, general and administrative expenses were 32.7% of revenue, versus 33.9% a year ago. Adjusted SG&A was 32.3% of revenue, compared with 33.3%. → Berkshire Boosts Its Bet: This AI Hyperscaler Is Now a Top-3 Holding GAAP operating income was $1.7 million, down from $2.1 million in the prior-year quarter. Adjusted operating income declined to $1.8 million from $2.5 million. GAAP net income was $1.3 million, or $0.10 per diluted share, compared with $2.0 million, or $0.15 per diluted share, a year earlier. On an adjusted basis, net income was $1.4 million, or $0.11 per diluted share, compared with $2.3 million, or $0.17 per diluted share, in the fourth quarter of fiscal 2025. Adjusted EBITDA declined to $2.7 million, or 6.5% of revenue, from $4.8 million, or 8.7% of revenue. Terrence Moorehead, who recently joined LifeVantage as president and chief executive officer, said his early review of the business reinforced his conviction in its differentiated science, balance sheet and potential for growth. He thanked Michael Beindorff for his stewardship during the leadership transition. Moorehead said the company’s initial priorities will center on strengthening the LifeVantage brand, building a more relevant consumer proposition and improving operational excellence and profitability. He said the company needs to communicate its scientific and product story more clearly and in a more consumer-friendly manner, while providing the sales force with stronger tools and improving the consumer experience. “We have compelling science, differentiated products, strong margins, and are targeting a passionate group of consumers that are looking for new ways to improve their health every single day,” Moorehead said. Management did not provide formal fiscal 2027 guidance because of the CEO transition. Aure said the company still faces difficult comparisons in the first and second fiscal quarters, but management expects strategies being developed to potentially contribute to improving momentum in the fiscal third and fourth quarters. Moorehead said consumers are facing price pressure from the broader economy. He said LifeVantage intends to strengthen its value proposition without necessarily lowering prices, including through better communication about its products. Moorehead said international markets represent an opportunity, though the company’s immediate focus is expected to be increasing penetration in existing markets rather than rapidly expanding its geographic footprint. He described a potential hub-and-spoke approach that would build penetration in anchor markets before expanding further, while also emphasizing the remaining opportunity in North America. Digital capabilities will be a key part of the company’s strategy, according to Moorehead. LifeVantage is working on upgrades to its website and consumer access points, alongside digital tools and assets intended to help its sales force operate more effectively. Capital expenditures totaled $3.6 million in fiscal 2026, compared with $1.4 million in fiscal 2025, driven primarily by technology infrastructure investment, including the Shopify integration. Aure said he expects fiscal 2027 capital spending to be slightly below fiscal 2026 levels, in a range of roughly $3 million to $3.5 million, as the company completes the final stages of the Shopify project. He said normal capital spending could return to a historical range of $2 million to $2.5 million once the project is completed. LifeVantage ended fiscal 2026 with $14.9 million in cash and no debt, compared with $20.2 million in cash a year earlier. It generated $10.2 million in cash from operations during the year, versus $11.9 million in fiscal 2025, and retained access to a $5 million revolving credit line. The company used $3.7 million of cash for the LoveBiome transaction during fiscal 2026. It also repurchased about 336,000 shares for $2 million during the year, including 85,700 shares for approximately $459,000 in the fourth quarter. As of June 30, $58.5 million remained under the company’s $60 million share repurchase authorization approved in January. LifeVantage also declared a quarterly cash dividend of $0.05 per common share, payable Sept. 15 to shareholders of record as of Sept. 1. LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company's flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs. Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Lifevantage Q4 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

SALT LAKE CITY, Aug. 21, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company’s Board of Directors has approved a quarterly cash dividend of $0.050 per share of common stock, which will be paid September 15, 2026 to all stockholders of record at the close of business on September 1, 2026. About LifeVantage Corporation LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the MindBody GLP-1 System®, the newest comprehensive gut activator from LoveBiome P84, the Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic and hydration energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com. Cautionary Note Regarding Forward Looking Statements This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," “may be,” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The declaration and/or payment of a dividend during any quarter provides no assurance as to future dividends, and the timing and amount of future dividends, if any, could vary significantly in comparison both to past dividends and to current expectations. Examples of forward-looking statements include, but are not limited to, statements we make regarding expected financial performance, including revenue and margins, executing against and the benefits of our key initiatives, future growth, including geographic and product expansion, expected financial performance, and expected dividend payments in future quarters. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, further deterioration to the global economic and operating environments, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission (the “SEC”). The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law. Investor Relations Contact: Reed Anderson, ICR(646) [email protected]

SALT LAKE CITY, Aug. 13, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its fourth quarter and full fiscal year ended June 30, 2026, after the stock market closes on Thursday, August 27, 2026. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day. Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, September 17, 2026, by dialing (844) 512-2921 from the U.S. and entering confirmation code 13761673, or (412) 317-6671 from international locations, and entering confirmation code 13761673. There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at https://lifevantage.gcs-web.com/events-and-presentations or directly at https://viavid.webcasts.com/starthere.jsp?ei=1769431&tp_key=4b4c303abc. The webcast will be archived for approximately 30 days. About LifeVantage Corporation LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, MindBody GLP-1 System™, and the comprehensive gut activator, P84, and activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com. Investor Relations Contact: Reed Anderson, ICR(646) [email protected]

LifeVantage Corporation (NASDAQ:LFVN) is included among the 12 Best Micro-Cap Dividend Stocks to Buy Now. On May 7, Lake Street downgraded LifeVantage Corporation (NASDAQ:LFVN) to Hold from Buy and set a $5 price target after the company reported weaker-than-expected Q3 results. The analyst said management kept its prior FY26 guidance framework in place but now expects results to land near the low end of the range. The firm also lowered its estimates below the company’s updated outlook. The analyst noted that while the stock valuation “remains inexpensive,” revenue headwinds were expected to continue for at least the next two quarters, which could limit upside potential. During the company’s fiscal Q3 2026 earnings call, Interim CEO & Director Michael Beindorff said LifeVantage had launched the VIP bonus program, calling it the company’s first 12-month volume growth incentive initiative for consultants. He explained that the program was designed to reward sales growth while also helping identify and elevate consultants to strengthen leadership within the organization. Beindorff also said the company was investing heavily in its e-commerce platform. He noted that the rollout of Shopify, along with a fully upgraded back-office system, was expected to improve the online experience for both customers and consultants. He added that the Shopify launch was planned for later this year. CFO Carl Aure said LifeVantage generated $43.7 million in net revenue during fiscal Q3 2026, down 25.2% from a year earlier. He said the decline was mainly tied to weaker sales of the MindBody GLP-1 System, though contributions from LoveBiome sales helped offset part of the drop. LifeVantage Corporation (NASDAQ:LFVN) is an activation company engaged in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and probiotics, skin and hair care products, and nootropics. While we acknowledge the potential of LFVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 14 Best Dividend Stocks to Buy for Steady Growth and 10 Best Robinhood Stocks to Buy According to Billionaires. Disclosure: None. Follow Insider Monkey on Google News.

Performance was significantly impacted by a decline in sales of the MINDBODY GLP-1 system, which management attributed to intense competitive dynamics within the GLP-1 market. The company is undergoing a major leadership transition with Michael Beindorff serving as Interim CEO following the retirement of Steve Fife, until Terrence Moorhead assumes the role in August. Management is prioritizing a 'foundational approach' to consultant growth, moving away from temporary sales spikes toward sustainable leadership development and authentic product advocacy. A significant multi-period investment in technology is underway, centered on migrating to Shopify and revamping back-office systems to modernize the end-to-end e-commerce experience. The acquisition of LoveBiome in October 2025 served as a strategic offset to revenue declines, integrating gut health as a core pillar of the product portfolio. Operational focus is shifting toward the 'VIP bonus' program, a 12-month incentive designed to identify and reward consultants demonstrating long-term leadership behaviors. Despite revenue contraction, the company maintains a debt-free balance sheet and cash reserves, providing the flexibility needed to fund strategic pivots and technology upgrades. Fiscal 2026 guidance has been narrowed to the lower end of previous ranges for revenue, adjusted EBITDA, and adjusted EPS due to current business trends and market competition. The Shopify platform rollout is expected to begin later this year with a staggered international approach, targeting full implementation starting in Q1 of the next fiscal year. Management anticipates a major 'hero product' launch at the annual convention in October 2024, following their typical 18-to-24-month innovation cadence. Full-year fiscal 2026 commissions and incentive expenses are projected to be approximately 42.5% of revenue, reflecting changes in customer mix and promotional timing. The company expects a full-year effective tax rate between 18% and 20% for fiscal 2026. Gross profit margin compressed to 79% from 81%, driven by increased shipping costs, warehouse expenses, and inventory obsolescence related to the MINDBODY system. The Board approved a new $60 million share repurchase authorization in January, with $59 million remaining as of the end of the third quarter. A quarterly cash dividend of $0.05 per share was announced, representing an 11% increase over the previous dividend amount. The company secured a U.S. patent for the Healthy Glow Essentials Stack, which management views as critical validation of their scientific differentiation in the nutrigenomics space. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management expects to generate approximately $5 million in cash from operations in Q4, consistent with the March quarter performance. CapEx is expected to remain at the current $1 million per quarter run rate for the next one to two quarters before declining as Shopify development costs phase out. The decline to 30,000 active consultants is being addressed by simplifying the business model and focusing on 'sticky' products like Protandim and Collagen. The new VIP program requires consultants to 'opt-in,' ensuring the incentive spend is targeted at leaders explicitly committed to growth rather than the general population. While recent focus has been on gut health via P84 and LoveBiome, the upcoming October product launch will likely address a different, complementary category. Management confirmed that P84 remains one of their four 'hero' product lines and will receive continued marketing support. The company remains committed to the $60 million authorization and intends to buy shares opportunistically based on current market valuations. Approximately $1 million was utilized for repurchases during the third quarter. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.